FOG-001 + leucovorin + 5-fluorouracil + oxaliplatin + bevacizumab

A combination regimen investigating **FOG-001**, a first-in-class Helicon peptide that acts as a competitive inhibitor of the protein-protein interaction between **β-catenin** and the **T-cell factor (TCF) family** of transcription factors, with standard chemotherapy agents **leucovorin**, **5-fluorouracil**, **oxaliplatin** (collectively known as FOLFOX), and the anti-angiogenic monoclonal antibody **bevacizumab**. FOG-001 disrupts Wnt/β-catenin pathway signaling, a mechanism frequently implicated in drug resistance and poor prognosis in colorectal cancer and other solid tumors. The regimen is designed for use in patients with advanced or metastatic solid tumors, primarily microsatellite-stable colorectal cancer, targeting both aberrant Wnt signaling and tumor angiogenesis. FOG-001 is developed by Parabilis Medicines and is currently in Phase 1/2 clinical trials in combination with FOLFOX and bevacizumab[1][3][5].